RareResearch.AI
← Back to atlas

H313Y

Category 4 — Stable Fold, Function DisruptedPathogenic/Likely pathogenicTransmembrane · predictedEditorial
HistidineTyrosine at position 313 · N-terminal cytoplasmic domain (87-313) · WFS1 (Wolframin)

Histidine-to-tyrosine substitution at the boundary between the N-terminal cytoplasmic domain and TM1 — borderline pLDDT (57) and a low AlphaMissense (0.167) sit in marked tension with ClinVar Pathogenic/Likely pathogenic, making H313Y a strong candidate for ClinVar reclassification review.

Interactive 3D Structure

Wild-type reference
Wild-type H313 — hydrogen bond to R309
Fullscreen ↗
DynaMut2 mutant · H313Y
Mutant Y313 — hydrogen bond contact to S316 lost
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

0 lost2 gained8 preserved
Interaction typeWild-type partnerMutant partnerStatus
Hydrogen bondR309R309Preserved
Hydrogen bondA310Gained
Hydrogen bondS316S316Preserved
Hydrogen bondT317T317Preserved
Polar contactR309R309Preserved
Polar contactA310A310Preserved
Polar contactS316S316Preserved
Polar contactT317T317Preserved
Van der WaalsT317T317Preserved
HydrophobicT317Gained

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
1.20kcal/mol
Stabilising — moderate
AlphaMissense
0.167
LBen
AlphaFold pLDDT
57
model confidence
Schema
Cat 4
Category 4 — Stable Fold, Function Disrupted
ΔΔG confidence: Low confidence · Transmembrane
  • transmembrane position; predictor benchmarked on soluble proteins
  • pLDDT 57.41 below 70

This variant sits in the transmembrane band. The stability value was computed with a predictor benchmarked on water-soluble proteins. Published benchmarks of ddG predictors on membrane proteins report correlation below 0.4. Treat the magnitude as unreliable and the sign as weak evidence only.

The underlying AlphaFold model has pLDDT below 70 at this position, so the structure the stability calculation was run on is itself uncertain.

Do not rank this value against a variant from a different region on ΔΔG alone.

Clinical Evidence

ClinVar classificationPathogenic/Likely pathogenic
Review statuscriteria provided, multiple submitters, no conflicts
Associated conditions(ClinVar conditions: not provided)
InheritanceInheritance pattern not explicitly recorded; ClinVar conditions listed as not provided.
Population frequency (gnomAD v4)Ultra-rare · AF 0.000068%
cDNA changec.937C>T
ClinVar accessionVCV000290817
Last evaluated2025/10/06 00:00

Observed at very low frequency in gnomAD.

Classified for2★ documented assertion

ClinVar classifies this variant as Pathogenic/Likely pathogenic, but does not state what it is classified for. ClinVar records the condition only as "not provided". A classification without a phenotype and an inheritance mode cannot be read as a statement about Wolfram syndrome risk or severity.

  • Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient.
  • Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

Review status: 2★ multiple submitters, no conflicts. ClinVar "conditions" is the union of all submissions; 0–1★ entries are submitted conditions, not documented phenotypes.

Population frequency
Global (all ancestries)
AF 0.000068% · 1 / 1,461,828 alleles
Homozygotes
0

Every ancestry group with observed alleles falls below the reporting threshold (min 2 alleles, min 500 sampled) — too sparse to name a highest-frequency population.

No homozygotes reported in gnomAD v4. For a recessive allele this is expected and is not, on its own, evidence either way.

Ancestry groupAllele freq.AC / ANHom.Carrier est.
East Asian · under-sampled0.0025%1 / 39,7000

Source: gnomAD r4, retrieved 2026-08-21. Values are allele frequencies. The carrier estimate is derived from the allele frequency (Hardy-Weinberg, ~2·AF) and is an approximation, not a published figure — where a published carrier frequency exists it outranks this column and is cited on the card.

Structural Context

H313 is held between Met312 (2.44 Angstrom) and Trp314 (2.47 Angstrom). Through-space contacts include Ser316 (3.63 Angstrom), Ala310 (3.92 Angstrom), Arg309 (4.00 Angstrom), Gly311 (4.50 Angstrom), and Leu315 (4.54 Angstrom). Trp314 is structurally striking — a tryptophan at the cytoplasmic edge of TM1 is the classical interfacial-anchor residue, embedding the membrane-helix start at the bilayer interface. The Met312-His313-Trp314 sequence places H313 at a hinge point: a sulfur-bearing residue, an imidazole, and an interfacial aromatic, all within a single short stretch.

Replacing H313 with tyrosine introduces a second large aromatic immediately next to the interfacial Trp314. Two large aromatics in sequence at a membrane interface can either pi-stack productively (potentially stabilizing the transition into TM1) or compete for the interfacial position (destabilizing the Trp314 anchor). DynaMut2 reports DeltaDeltaG = +1.20 kcal/mol — stabilising, larger magnitude than most variants in this batch. The energy function is reading a productive Tyr313-Trp314 aromatic interaction.

AlphaMissense, in striking contrast, scores H313Y at 0.167 — Likely Benign, well below the 0.564 pathogenicity threshold. The discordance with ClinVar Pathogenic/Likely pathogenic is even sharper than for E202G. Possible reconciliations: (a) the variant is genuinely benign and ClinVar's pathogenicity classification was driven by limited evidence that may warrant reclassification; (b) the Atlas's metrics are underweighing a real functional consequence at the cytoplasmic-TM1 boundary; (c) ClinVar evidence reflects compound-heterozygous cases where H313Y is not the causal allele.

The stabilising DeltaDeltaG, the low AM score, and the structurally plausible Tyr-Trp aromatic interaction together suggest the variant may indeed be functionally tolerated. The Atlas should flag H313Y for ClinVar evidence review rather than confidently assign druggability category.

Amino-acid chemistry
Histidine (imidazole side chain, pKa ~6, conditionally polar) to Tyrosine (large aromatic phenol, polar hydroxyl, ring system roughly twice the volume of imidazole) at position 313. The substitution exchanges a small polar imidazole for a much larger aromatic phenol.
Position in the protein
Position 313 sits at the very C-terminal edge of the N-terminal cytoplasmic domain (residues 87-313) and immediately adjacent to TM1 (residues 314-334). This is a domain-boundary residue, structurally and functionally a transition point. pLDDT 57.41 is borderline — above the IDR exclusion threshold (50) but well below confident folding territory.

Druggability Assessment

Final classification: Category 4 — Stable Fold, Function Disrupted (assigned by the schema), with strong metric-discordance flag. The schema's category assignment reflects the DynaMut2 magnitude criterion, but every other metric (low AM score, stabilising DeltaDeltaG, borderline pLDDT, no listed clinical conditions) argues against confident pathogenicity. For druggability, the right Atlas behavior is to defer therapeutic investment until the ClinVar classification is re-validated. If the variant is genuinely pathogenic, the cytoplasmic-TM1 boundary lesion is potentially small-molecule-accessible. If the variant is benign or a co-segregating bystander, no therapeutic effort is warranted. The clinical-genetics community is increasingly attentive to reclassification of single-submission P/LP variants, and H313Y fits the reclassification-candidate profile.

Why this matters

H313Y is the Atlas's most striking metric-discordant variant in this batch: ClinVar P/LP, but AlphaMissense Likely Benign, DynaMut2 stabilising, borderline pLDDT, and no listed associated conditions. The honest scientific position is that the available evidence does not support confident pathogenicity, and the Atlas should communicate this directly. This kind of disclosure is precisely the differentiating value of a curated public atlas over an automated database aggregator. The clinical user benefits from knowing that two independent computational pathogenicity predictors and the structural data all argue against a clinical classification that the Atlas is honoring only because ClinVar holds it. Transparency here builds the kind of trust the atlas.rareresearch.ai platform needs to be credible to the rare-disease clinical community.
Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the H313Y PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download H313Y PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.

UniProt Domain Annotation

Chain1890 · Wolframin
Region1321 · Interaction with ATP6V1A